BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dalton Medicinal Chemistry Partners Receives Notice of Award From National Institute on Drug Abuse (NIDA) of National Institutes of Health (NIH) to Fund Research


3/27/2013 11:49:47 AM

(PRWEB) March 27, 2013 -- Toronto, ON March 27, 2013 -- Dalton Medicinal Chemistry has received notice of award from the National Institute On Drug Abuse (NIDA) to research and discover a novel series of compounds with the potential to treat drug abuse and alleviate pain.

This work will be supported by NIDA of the National Institutes of Health (NIH) under Award Number R21DA036251 which includes funding for the project. Dalton Medicinal Chemistry will utilize their proprietary knowledge and expertise to design, synthesize and test several novel classes of compounds for these applications. The goal of this research work is to identify and establish candidates for further development towards a future drug product.

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: “It is exceptionally exciting to receive notice of this competitive award from National Institute On Drug Abuse (NIDA) which germinated from the creative insights of the talented scientists at Dalton. We are delighted to have the opportunity to initiate and conduct this important research.”

The content of this release is the responsibility of the authors and does not represent the official views of the National Institutes of Health.

About Dalton Medicinal Chemistry

Dalton Medicinal Chemistry Incorporated (DMC) was established to offer select partners medicinal chemistry capabilities in design and synthesis of new chemical entities. DMC focuses on quality, creativity and speed in the delivery of innovative, high quality medicinal chemistry capabilities for the identification of new chemical entities which advance our clients' drug discovery programs. Our contributions to clinical development candidate selection include SAR elucidation, design and synthesis of focused compound arrays, hit to lead, lead optimization and generation of intellectual property. DMC works directly with Dalton Pharma Services (DPS) and its industry leading chemistry laboratories for synthetic chemistry, structural determinations and purity assessments.

About Dalton Pharma Services

Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its modern cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts aseptic fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.

For more information, please visit: http://www.dalton.com.

For further information contact:

Peter Pekos

President & CEO

Dalton Pharma Services

349 Wildcat Road

Toronto, Ontario

Tel: 416-661-2102

Fax: 416-661-2108



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES